Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

Could Merck/Kelun Come Out On Top?

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

• Source: Shutterstock

Emerging data on the field of TROP2-targeted antibody-drug conjugates – namely Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy), Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s (datopotamab deruxtecan (Dato-DXd) and Merck & Co., Inc./Sichuan Kelun Pharmaceutical Co Ltd.’s sacituzumab tirumotecan (Sac-TMT) – suggest that developers need to aim for subgroups of non-small cell lung cancer rather than all-comers, and that the drugs are more likely to work in earlier-line disease combined with checkpoint inhibitors.

Key Takeaways
  • ASCO featured Phase II and Phase III data from three competing TROP2-directed ADCs in non-small cell lung cancer, giving a glimpse of the future competitive field.

Detailed data from Gilead’s failed Phase III EVOKE-01 trial of Trodelvy, the investigator-sponsored Phase II ICARUS-Lung01 trial of Dato-DXd and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Conferences

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.